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Abstract: Cancer-stem-cell theory states that most, if not all, cancers arise from a stem/uncommitted
cell. This theory revolutionised our view to reflect that cancer consists of a hierarchy of cells that
mimic normal cell development. Elegant studies of twins who both developed acute lymphoblastic
leukaemia in childhood revealed that at least two genomic insults are required for cancer to develop.
These ‘hits’ do not appear to confer a growth advantage to cancer cells, nor do cancer cells appear to
be better equipped to survive than normal cells. Cancer cells created by investigators by introducing
specific genomic insults generally belong to one cell lineage. For example, transgenic mice in which
the LIM-only 2 (LMO2, associated with human acute T-lymphoblastic leukaemia) and BCR-ABLp210
(associated with human chronic myeloid leukaemia) oncogenes were active solely within the
haematopoietic stem-cell compartment developed T-lymphocyte and neutrophil lineage-restricted
leukaemia, respectively. This recapitulated the human form of these diseases. This ‘hardwiring’
of lineage affiliation, either throughout leukaemic stem cell development or at a particular stage,
is different to the behaviour of normal haematopoietic stem cells. While normal cells directly commit to
a developmental pathway, they also remain versatile and can develop into a terminally differentiated
cell that is not part of the initial lineage. Many cancer stem cells do not have this versatility, and this
is an essential difference between normal and cancer stem cells. In this report, we review findings
that support this notion.
Keywords: leukaemia; stem cells; haematopoiesis; lineage decision making; oncogenes; cancer
1. Introduction
The precise cellular origin of a cancer, and the ability of the underlying cell to differentiate dictate
the course of overt disease. This, in turn, influences how well patients respond to their treatment.
The specific type of cell in which a cancer originates, the cancer-initiating cell (CIC), has been of
longstanding interest to scientists and clinicians. Even now, the identity of this cell is unclear in
some cancers. In the late 1990s, John Dick and his colleagues proposed cancer-stem-cell theory on
the basis of evidence from studies of acute myeloid leukaemia (AML). They stated that most, if not
all, cancers arise from genetic lesions involving a tissue-specific stem cell [1]. In the case of AML,
the leukaemia-initiating cell (LIC) was a pluripotent haematopoietic stem cell (HSC). John Dick’s
proposal was keeping with the view that HSCs and their progeny (haematopoietic progenitor cells,
HPCs) were prime targets for malignant transformation due to their inherent properties of self-renewal,
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long life, and proliferative potential. To this day, investigators also view mature B and T lymphocytes
as targets for malignancy by virtue of their proliferative potential [2].
There are two key cells with regard to the development of cancer, CICs and cancer stem cells (CSCs).
These cells are often confused. Some 100 years ago, Boveri observed chromosomal abnormalities in
cancer cells [3]. Investigators identified further lesions in the 1950s and 1960s, leading to the view that
the underlying driver of the development of cancer was an insult to the genome. Around this time,
cancer modelling also began to include the concept of cancer initiation (preneoplasia) in addition to
overt disease (malignancy). Subsequently, elegant studies of identical twins who had both developed
acute lymphoblastic leukaemia (ALL) in childhood revealed that at least two insults to the genome were
required for the development of leukaemia [4]. This was in part due to the intraplacental sharing of
a preleukaemic clone containing an identical chromosomal translocation. However, disease occurrence
is asynchronous, and therefore requires one prenatal and one (or more) postnatal genomic ‘hits’.
The first ‘hit’ converts the LIC, thought to be a B-lymphocyte-committed progenitor in the case of ALL
(see below), into a dormant preleukaemic cell. A further ‘hit’ then converts this cell into a leukaemic
stem cell (LSC) that gives rise to and sustains the disease.
2. Nature of Cancer Stems Cells and Their Progeny
A clear picture of the behaviour of LICs/CICs and LSCs/CSCs is important to finding better
treatments for malignancies. This is because LSCs are mostly responsible for untreatable disease
relapses in AML, and CSCs underlie carcinoma relapse and metastasis. The elimination of CSCs
might provide a means to find a cure for carcinomas that are difficult to treat. However, we do not
currently have a clear picture of how two or more ‘hits’ transform a normal stem cell into a cancer
cell. For example, we do not know if there is a difference between LIC and normal HSC behaviour in
childhood ALL. Analysis of leukaemic cells at the time of patient presentation does not provide direct
insight into the nature of LICs because the disease process begins many years prior, and the mutational
burden is then too high.
CSCs constitute a small fraction of a patient’s cancer cells. The percentage ranges from very small
to up to 25% for different types of cancers [5–7], meaning that more mature progeny form the bulk
of a patient’s cancer cells. Investigations of HSCs and haematopoiesis have provided the current
paradigm of normal stem-cell development and the nature of their progeny. Many longstanding and
classical models of haematopoiesis depict a binary cell-fate tree in which the progeny of HSCs and
HPCs progressively restrict their developmental options to give rise to end-cell types (see below).
Investigators also use this type of model to describe the development of other tissue-specific stem cells.
Human AML is composed of a hierarchy of cells that originate from a transformed HSC [8] that has
differentiated to variable degrees to make up the bulk of a patient’s leukaemic cells.
The behaviour of the bulk of a patient’s cancer cells might elucidate the difference between normal
stem cells and CSCs. An early view on the nature of cancer cells arose from the first descriptions of
patients with leukaemia by Bennet and Virkow. They reported a high density of white cells in blood
and concluded that leukaemic cells divide extensively and/or quickly, and that the abundance of cells
might be a response to infection. Rapid cell division at diagnosis is rare because many cancers are
indolent, meaning they take time to become evident. The combined ‘hits’, therefore, do not necessarily
confer a growth advantage to CICs/CSCs. Though cancers originate from a single transformed cell,
the progeny are dynamic and undergo clonal evolution that has major implications for curing advanced
cancers. Despite their diversity, cancer cells do not appear to be better equipped to survive. This was
shown in a study where cancer subclones seldom demonstrated survival advantages over one another
at the time of patient diagnosis [8]. The differentiation of cancer cells is often perturbed, which has
led to the view that there is a skewing of cellular controls to favour proliferation over maturation.
However, given that there are numerous factors controlling proliferation and maturation within
cells [9,10], a proliferation increase at the expense of maturation is perhaps not a hallmark feature of
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cancer. Strikingly, leukaemic and carcinoma cells, including those arising from a stem cell, generally
belong to one cell lineage. The following review examines whether this is a cardinal feature of cancer.
3. Leukaemic Cells Belong to One Lineage
The nature of a patient’s cells in chronic myeloid leukaemia (CML) clearly illustrates that an LSC
can ‘dump’ cells down one lineage pathway. CML was shown to be a disease of HSCs by Fialkow,
who used cells from female patients and X-linked glucose-6-phosphate to reveal that a wide spectrum of
blood cell types belong to a leukaemic clone [11]. Despite this finding, patients’ cells were substantially
restricted to the neutrophil pathway. Similarly, acute erythroid leukaemia is an HSC disease, and ≥80%
of bone marrow cells are erythroid precursors [12].
Cell surface markers, particularly those identified by monoclonal antibodies, have provided a vital
tool to determine the precise nature of leukaemic cells. Owing to these markers, an understanding
of cell-lineage affiliation has advanced far more in leukaemia than in some other cancers. However,
for some human leukaemia types, the common belief about a cell of origin is at odds with
experiment evidence that supports earlier HSC origin. As mentioned above, ALL arises from
a B-lymphocyte-committed progenitor [13]. In contrast, HSC-like cells that express marker CD34+
and lack B-lineage markers recreate the disease in mice [14]. We view acute promyelocytic leukaemia
(APL) as a myeloid progenitor malignancy [15], with its hallmark feature being a t(15;17) chromosomal
translocation giving rise to the PML-RARα oncoprotein. The translocation and oncoprotein are both
present in CD34+CD38− HSC-like cells in patients with APL [16]. It has been a longstanding belief that
chronic lymphocytic leukaemia (CLL) is a malignancy of small B-lymphocytes. However, abnormal
expression of lymphoid genes in patients’ HSCs, and the fact that HSCs purified from patients with
CLL produce a high number of polyclonal B-cell progenitors, indicate an HSC origin [17].
Coupled to the assertion that leukaemic cells belong to one cell lineage, as defined by histological
features and immunological markers, is that unique chromosomal abnormalities are also present.
As stated above, the bulk of CML patients’ cells are relatively mature neutrophils. Hungerford and
Novell described a specific chromosomal abnormality that is associated with CML—a small version of
chromosome 21, termed the Philadelphia chromosome [18]. Since this discovery, the development of
a high-resolution technique for chromosomal analysis and fluorescence in situ hybridisation (FISH)
has led to the discovery of many other chromosomal abnormalities that result in hybrid genes
consisting of portions of two different genes. In some cases, multiple different types of cancer express
the same hybrid gene, indicating that these genes can play a role in the cancers of different tissue
types. Like CML, some chromosomal abnormalities are specifically associated with the histological
subtype of a malignancy, such as those seen in non-Hodgkin’s lymphoma. Specifically, a translocation
between chromosomes 18 and 14 is seen in patients with follicular lymphoma, and a translocation
between chromosomes 8 and 14 is seen in patients with small-noncleaved-cell and large immunoblastic
lymphoma [19]. Chromosomal translocations between chromosomes 11 and 14, 11 and 13, and 7
and 11 activate the LMO2 gene, the product of which is a specific marker of T-cell ALL (T-ALL) [20].
A translocation between chromosomes 12 and 21, creating the ETV6-RUNX1 fusion gene, is associated
with B-cell ALL (B-ALL) [21].
Investigators have been able to reproduce in mice the genotype–phenotype associations found in
some human leukaemias by restricting the expression of a specific oncogene to the stem-/progenitor-cell
compartment. Though leukaemia arises in a primitive cell, leukaemic cells belong to a particular cell
lineage. Examples of this association in haematopoietic malignancies include BCR-ABLp210 in CML [22],
MAFB in multiple myeloma [23], and BCL6 in B-cell neoplasia [24]. Examples of this association in
solid tumours include EWS-FL1-1 in Ewing sarcoma [25] and SYT-SSX2 in synovial sarcoma [26].
In these instances, a specific genetic insult to a stem/progenitor cell is associated with a particular
cancer. The BCR-ABLp190, LMO2, and BCR-ABLp210 oncogenes play a role in human B-lymphocyte,
acute T-lymphoblastic, and chronic myeloid leukaemia, respectively. In transgenic mice in which the
expression of BCR-ABLp190, LMO2, and BCR-ABLp210 was restricted to HSCs via the Sca-1 promotor,
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carcinogenesis was initiated by the oncogenes, and the resultant cancer recapitulated lineage-restricted
human disease [27–29]. In transgenic mice, the oncogene is solely active within LICs/LSCs and is
therefore not essential for the survival and/or proliferation of more mature lineage-affiliated leukaemic
cells. An interpretation of these findings is that the oncogene ‘hardwires’ lineage affiliation either
throughout or at a particular stage of LSC development, thus restricting the leukaemic cells to that
pathway (Figure 1) [30]. This may occur via the oncogene-mediated priming of the epigenome in cells
to adopt a single cell lineage [29,30].
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BCR-ABLp190, LMO2, and BCR-ABLp210 o cogenes play a role in human B-lymphocyte, acute
T-lymphoblastic, and chronic myeloid leukaemia, respectively. Studies of transgenic ice in hich
investigators used Sca-1 promotor to restrict oncogene expression to haematopoietic stem cells showed
that oncogenes initiated leukaemia development and recapitulated lineage-restricted human disease.
While we argue that specific oncogenes/genomic insults to HSCs give rise to a particular
lineage-restricted type of leukaemia, there are some caveats to extending this assertion to other
types of cancer. Leukaemias could be unique in their specific genomic/epigenetic insults that serve
to drive the transformed HSC along a particular developmental pathway. In addition, a specific
insult/chromosomal abnormality is not seen in all cancers. This is especially true of solid tumours.
We argue that some leukaemia types have an earlier HSC origin than traditionally thought, but that
a lineage-committed progenitor cell may be the origin of some solid tumours. In this case, lineage
affiliation is equated to the cell of origin, whereby the cell of origin dedifferentiates to regain stemness
while retaining a close lineage affiliation. An argument against this view is that committed epithelial
cells can give rise to malignant squamous cell carcinomas despite the absence of an oncogene to revert
these cells to a stem-cell-like state [31]. However, it does seem that stem cells are usually the origin of
‘successful’ squamous malignancies.
There are malignancies in which the simultaneous expression of cell surface markers of different
cell types confers a mixed lineage status. Coexpression of markers belonging to at least two lineages
is seen in mixed-phenotype acute leukaemia (MPAL). This is a rare subgroup of acute leukaemia
(2%–5%) in which cells express myeloid and B- or T-lymphoid markers, or myeloid, B-, and T-lymphoid
markers together. MPAL might seem to contradict the oncogene-driven ‘hardwiring’ of HSCs to a cell
lineage. However, our understanding of MPAL is still very limited because the causative cells are of
ambiguous lineage and origin. It is not known whether it is more effective to treat MPAL patients
with acute myeloid or acute lymphoid regimens. The surface expression of lineage markers might not
Int. J. Mol. Sci. 2020, 21, 45 5 of 10
reliably define the predominant cell type in MPAL. Indeed, clinicians consider some cases of MPAL
to be acute myeloid leukaemia at diagnosis, with the expression of lymphoid markers being due to
inappropriate gene expression [32]. As mentioned above, ETV6-RUNX1 is associated with B-ALL
despite blast cells expressing myeloid markers [33,34]. The same applies to BCR-ABL190 in B-ALL [35].
We view both of these leukaemias as being primarily of a B-lineage restricted cell with aberrant gene
expression. Other hybrid states include the epithelial–mesenchymal transition, whereby a polarised
epithelial cell undergoes changes to assume a mesenchymal-cell phenotype. This is seen in cancer
cells at the invasive front of a tumour, where they convert to a mesenchymal phenotype to spread to
other organs. We consider this transition somewhat different to the malignant transformation of HSCs
because the epithelial–mesenchymal transition occurs during development and adulthood as a means
of generating more cells [36].
There are leukaemias and solid cancers in which malignant cells are clearly a mixture of more than
one cell type. A striking example is the transformation of embryonic stem cells to give rise to teratomas
consisting of multiple cell types. This is also the case for the transformation of induced pluripotent cells
(iPSCs). iPSC-derived teratomas resemble benign teratomas that occur in mice and humans during
early life [37]. We consider them ‘unsuccessful’ malignancies and excluded them from consideration
with regard to lineage fixation. The classification and origin of spontaneous teratomas in humans is
complex and unclear. Some types seem to arise from multiple defects during germline development [37].
As such, their development does not seem to be initiated by an oncogene-driven event.
4. Do Normal Stem Cells Behave Differently?
As mentioned above, investigators have used treelike models for many years to describe the
development of HSCs. In recent years, our view has radically changed. We previously viewed
HSCs as a pluripotent population of cells. Branch points in treelike models of haematopoiesis
dictate routes that individual HSCs follow towards each end-cell fate via a series of intermediate
HPCs. The final step involves commitment to a single lineage. However, HSCs selectively
express lineage-associated receptors on their surface: for erythropoietin (Epo) [38], macrophage
colony-stimulating factor (M-CSF) [39–41], granulocyte colony-stimulating factor (G-CSF) [42],
granulocyte/macrophage colony-stimulating factor (GM-CSF) [39], and FMS-like tyrosine kinase
3 ligand (Flt3L) [41]. In keeping with findings that support the initiation of lineage affiliation earlier
than previously thought (Figure 2), recent studies have shown that, within HSCS, human adult
bone-marrow CD34+ cells include pluripotent cells and cells with unipotent myeloid or erythroid
potential. In this case, the downstream progeny of HSCs that we have routinely considered to be a single
population of cells on the basis of cell surface markers could also be a mixture of cells with lineage
signatures. This is true for the population of cells first described as early progenitors with lymphoid
and myeloid potential (EPLM) [43]. RNA sequencing of single cells in a ‘primitive’ subpopulation of
EPLM that lacked expression of markers Ly6D, SiglecH, and CD11c revealed that the subpopulation
was composed of cells with a myeloid, dendritic cell, or lymphoid signature. Few cells had lymphoid
and myeloid potential [44].
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Figure 2. Continuum haematopoiesis model. In our model, haemopoietic stem cells (HSCs) are
a mixture of cells with different lineage signatures (shown by different colours) that ‘choose’ a lineage
from all options. HSCs and haematopoietic progenitor cells (HPCs) retain enough versatility to ‘step
sideways’ into a different pathway. Erythropoietin (Epo), granulocyte colony-stimulating factor (G-CSF)
and granulocyte/macrophage colony-stimulating factor (GM-CSF), and macrophage colony stimulating
factor (M-CSF) can induce erythroid, neutrophil, and monocyte fates, respectively, within HSCs/HPCs.
Our ‘developmental’ view of haematopoiesis is that an HSC selects one lineage from a continuum
of all end-cell options, and then differentiates to that cell type (Figure 2). We provided evidence to
support our viewpoint elsewhere [45–47]. Though the model shows that affiliation/commitment to
a cell lineage can occur as early as during the HSC stage, haematopoiesis still remains dynamic. HSCs
and HPCs can still ‘change their mind’ and adopt an alternative fate. Megakaryocyte-primed HSCs can
‘step sideways’ to erythropoiesis, as there is a ‘shared’ trajectory in these pathways due to a common
dependence on transcription factor GATA-1 [48]. Investigators found that cells are able to move to the
left or right of a chosen trajectory in the erythroid, granulocytic/macrophage, and lymphoid pathways.
They established this by using the RNA sequencing of more than 1600 single HSCs and HPCs to
construct expression maps [49].
With regard to HPCs, it was shown that mouse progenitor thymocytes that are well on their way to
becoming T cells are not firmly restricted to this option—they can still give rise to macrophages, natural
killer cells, and B-lymphocytes. The presence of an appropriate cytokine (e.g., M-CSF for macrophages)
is essential to divert their fate in vitro (see below) [50]. Dispersal of HPCs from the bone marrow in
a semisolid medium with the addition of particular growth factors (colony-stimulating factors) leads
to the production of colonies containing various cell types depending on the added growth factor(s).
We argued that the single cell giving rise to the colony ‘shuﬄes sideways’ to adopt various pathways
because it is out of its normal environment with regard to the control of cell fate [46]. Single-cell
analysis of mixed-lineage states has led to the proposal that bursts of alternative gene expression are
an important feature of cell decision making, including the existence of bilineage states [51].
As mentioned above, the presence of M-CSF is required to derive macrophages from thymocyte
progenitors. The selective expression of cytokine receptors by HSCs is relevant to how they ‘choose’
to follow a pathway of development. We formerly viewed all the above cytokines as survival and
growth factors for cells that are committed to a certain cell lineage(s). We now know that they
also instruct lineage choice. Epo commits multipotent HPCs to erythropoiesis [52]. M-CSF induces
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a myeloid lineage fate in HSCs [40], and a macrophage fate in granulocyte/macrophage progenitors [53].
G-CSF and GM-CSF induce the generation of neutrophils from granulocyte/macrophage progenitors
(Figure 2) [53,54]. Flt3L drives the myeloid–lymphoid development of primitive mouse bone-marrow
cells, suppressing the generation of megakaryocyte and erythroid progenitors [55]. Like normal
haematopoietic cells, leukaemic cells (e.g., AML cells) depend on the presence of growth factors and
an appropriate environment for their survival [56]. Therefore, we must assume growth factors are
readily available. A supply of haematopoietic cytokines may continuously ‘shape’ the production of
various types of blood cells to meet the overall demand of an organism. This may include diverting
HSCs/HPCs towards a certain cell type to deal with particular circumstances or infectious agents [46].
For example, HSCs, rather than multipotent HPCs, drive erythropoiesis during chronic erythroid
stress in Epo-transgenic mice. These mice demonstrate enhanced cell division, with HSCs exhibiting
a committed erythroid progenitor profile [57].
5. Concluding Remarks
Given the above evidence, the first oncogenic insult to a tissue-specific stem cell initiates
carcinogenesis by restricting lineage choices of LSCs and other CSCs, and directing their progeny
into a single developmental pathway [30,58]. In this scenario, LSCs/CSCs and their progeny lack
the versatility of HSCs/HPCs, which is an essential difference between normal and cancer stem cells.
However, several components of this phenomenon are poorly understood. Specifically, the degree to
which LSCs/CSCs are restricted is unknown, and, in other words, whether they are restricted from
all other fate options. The ability to ‘unlock’ these cells from their fates should also be investigated.
As stated above, we now know that Epo, M-CSF, G-CSF, GM-CSF, and Flt3L induce a specific cell
lineage. We can use these cytokines to test whether they are able to redirect the differentiation of mouse
LSCs in B-lymphocyte and T-lymphocyte leukaemias, and whether Epo can divert LSCs in myeloid
leukaemia towards erythropoiesis. In addition, by dissecting how epigenetic priming plays a role
in the risk and clinical course of leukaemia, we may be able to intervene by developing epigenetic
modifiers. Unlike genetic changes, epigenetic changes can be manipulated in order to treat patients
and even before a preleukaemic cell has evolved into leukaemia.
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